AR110796A2 - Derivados de bencilbenceno - Google Patents
Derivados de bencilbencenoInfo
- Publication number
- AR110796A2 AR110796A2 ARP180100278A ARP180100278A AR110796A2 AR 110796 A2 AR110796 A2 AR 110796A2 AR P180100278 A ARP180100278 A AR P180100278A AR P180100278 A ARP180100278 A AR P180100278A AR 110796 A2 AR110796 A2 AR 110796A2
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- optionally
- group
- groups
- Prior art date
Links
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 33
- 125000000217 alkyl group Chemical group 0.000 abstract 21
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 18
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 12
- 229910052739 hydrogen Inorganic materials 0.000 abstract 12
- 229910052760 oxygen Inorganic materials 0.000 abstract 12
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 11
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 10
- 229910052717 sulfur Inorganic materials 0.000 abstract 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 7
- 239000001301 oxygen Substances 0.000 abstract 7
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 abstract 6
- -1 chloro, hydroxy Chemical group 0.000 abstract 6
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 6
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 6
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 5
- 125000003342 alkenyl group Chemical group 0.000 abstract 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 5
- 239000011593 sulfur Substances 0.000 abstract 5
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 125000004450 alkenylene group Chemical group 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 4
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 4
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 4
- 229910002091 carbon monoxide Inorganic materials 0.000 abstract 4
- 125000005724 cycloalkenylene group Chemical group 0.000 abstract 4
- 125000004465 cycloalkenyloxy group Chemical group 0.000 abstract 4
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 abstract 4
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 abstract 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 3
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 abstract 3
- 125000005137 alkenylsulfonyl group Chemical group 0.000 abstract 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 3
- 125000005100 aryl amino carbonyl group Chemical group 0.000 abstract 3
- 125000005243 carbonyl alkyl group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000005222 heteroarylaminocarbonyl group Chemical group 0.000 abstract 3
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 abstract 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 2
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 abstract 2
- 125000006586 (C3-C10) cycloalkylene group Chemical group 0.000 abstract 2
- 125000005135 aryl sulfinyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 abstract 2
- 239000000460 chlorine Substances 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 239000011737 fluorine Substances 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000005150 heteroarylsulfinyl group Chemical group 0.000 abstract 2
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 abstract 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 abstract 1
- 125000004419 alkynylene group Chemical group 0.000 abstract 1
- 125000005133 alkynyloxy group Chemical group 0.000 abstract 1
- 125000005139 alkynylsulfonyl group Chemical group 0.000 abstract 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 abstract 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 abstract 1
- 125000006576 di-(C1-C3-alkyl)-aminocarbonyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto que es de la fórmula (1), en donde V es un miembro seleccionado del grupo formado por oxígeno; azufre; SO; SO₂; y un enlace simple; W es un miembro seleccionado del grupo formado por alquileno C₁₋₆, alquenileno C₂₋₆, alquinileno C₂₋₆, cicloalquileno C₃₋₁₀, cicloalquenileno C₅₋₁₀ y (cicloalquileno C₃₋₁₀)(alquileno C₁₋₆) donde la porción cicloalquileno C₃₋₁₀ se une a V y la porción alquileno C₁₋₆, se une a X, y donde los grupos o porciones alquileno, alquenileno, alquinileno, cicloalquileno y cicloalquenileno opcionalmente están parcial o totalmente fluorados y están opcionalmente mono- o disustituidos con sustituyentes independientemente seleccionados del grupo formado por cloro, hidroxi, alquilo C₁₋₃, alcoxi C₁₋₃, cicloalquilo C₃₋₆, cicloalquiloxi C₃₋₆, cicloalquenilo C₅₋₁₀ o cicloalqueniloxi C₅₋₁₀, y en los grupos o porciones cicloalquileno y cicloalquenileno, uno o dos grupos metileno están opcionalmente reemplazados, independientemente entre sí, por O, S, CO, SO, SO₂ o NRᵇ, y uno o dos grupos metino están opcionalmente reemplazados por N; X es un miembro seleccionado del grupo formado por oxígeno; azufre; SO; o SO₂; Y es un miembro seleccionado del grupo formado por hidrógeno, alquilo C₁₋₆, haloalquilo C₁₋₆, hidroxialquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₁₀, cicloalquenilo C₅₋₁₀, (cicloalquil C₃₋₁₀)alquilo C₁₋₄, (cicloalquenil C₅₋₁₀)alquilo C₁₋₃, (cicloalquil C₃₋₁₀)alquenilo C₂₋₄, cicloalquilidenmetilo C₃₋₆, (cicloalquenil C₅₋₁₀)alquenilo C₂₋₄, (alquiloxi C₁₋₄)alquilo C₁₋₃, (alqueniloxi C₂₋₄)alquilo C₁₋₃, (cicloalquiloxi C₃₋₁₀)alquilo C₁₋₃, (cicloalqueniloxi C₅₋₁₀)alquilo C₁₋₃, (amino)alquilo C₁₋₃, (alquilamino C₁₋₄)alquilo C₁₋₃, di-(alquilamino C₁₋₃)alquilo C₁₋₃, (alquil C₁₋₆)carbonilalquilo C₁₋₃, (alquenil C₂₋₆)carbonilalquilo C₁₋₃, (alquinil C₂₋₆)carbonilalquilo C₁₋₃, (arilcarbonil)alquilo C₁₋₃, (heteroarilcarbonil)alquilo C₁₋₃, (alquilsulfonil C₁₋₆)alquilo C₁₋₃, (alquenilsulfonil C₂₋₆)alquilo C₁₋₃, (alquinilsulfonil C₂₋₆)alquilo C₁₋₃, (arilsulfonil)alquilo C₁₋₃, (heteroarilsulfonil)alquilo C₁₋₃, (alquil C₁₋₆)aminocarbonilalquilo C₁₋₃, (alquenil C₂₋₆)aminocarbonilalquilo C₁₋₃, (alquinil C₂₋₆)aminocarbonilalquilo C₁₋₃, (arilaminocarbonil)alquilo C₁₋₃, (heteroarilaminocarbonil)alquilo C₁₋₃, (alquil C₁₋₆)carbonilo, (alquenil C₂₋₆)carbonilo, (alquinil C₂₋₆)carbonilo, arilcarbonilo, heteroarilcarbonilo, (alquil C₁₋₆)sulfonilo, (alquenil C₂₋₆)sulfonilo, (alquinil C₂₋₆)sulfonilo, arilsulfonilo o heteroarilsulfonilo; donde los grupos o porciones alquilo, alquenilo, alquinilo, cicloalquilo y cicloalquenilo opcionalmente están parcial o totalmente fluorados y opcionalmente están mono- o disustituidos con sustituyentes independientemente seleccionados del grupo formado por cloro, hidroxi, alquilo C₁₋₃, alcoxi C₁₋₃, cicloalquilo C₃₋₆, cicloalquiloxi C₃₋₆, cicloalquenilo C₅₋₁₀, cicloalqueniloxi C₅₋₁₀, y NRᵇRᶜ, y en los grupos o porciones cicloalquilo y cicloalquenilo uno o dos grupos metileno están opcionalmente reemplazados, independientemente entre sí, por O, S, CO, SO, SO₂ o NRᵇ, y uno o dos grupos metino están opcionalmente reemplazados por N, donde el heterociclo formado por dicho reemplazo opcional no es heteroarilo, y donde cuando V es un miembro seleccionado del grupo formado por oxígeno, azufre o un enlace simple y W es alquileno C₁₋₆, entonces Y no es hidrógeno, o alquilo C₁₋₆, y cuando V es oxígeno, W es cicloalquileno C₃₋₁₀ y X es oxígeno, entonces Y es diferente de hidrógeno, alquilo C₁₋₆, o trifluorometilo, y cuando V es un enlace simple y W es un miembro seleccionado a partir del grupo formado por alquenileno C₂₋₆, alquinileno C₂₋₆, cicloalquileno C₃₋₁₀ y cicloalquenileno C₅₋₁₀, entonces Y no es hidrógeno, alquilo C₁₋₆ o (cicloalquil C₃₋₁₀)alquilo C₁₋₄; y cuando V es un miembro seleccionado del grupo formado por oxígeno, azufre, SO o SO₂, W es un miembro seleccionado a partir del grupo formado por alquenileno C₂₋₆ o alquinileno C₂₋₆, e Y es un miembro seleccionado a parir del grupo formado por cicloalquilo C₃₋₁₀ o cicloalquenilo C₅₋₁₀, entonces X también puede representar un enlace simple; u opcionalmente X es NRᵃ e Y es un miembro seleccionado a partir del grupo formado por alquilsulfonilo C₁₋₆, alquenilsulfonilo C₂₋₆, alquinilsulfonilo C₂₋₆, arilsulfonilo, heteroarilsulfonilo, alquilsulfinilo C₁₋₆, arilsulfinilo, heteroarilsulfinilo, (alquil C₁₋₆)carbonilo, (alquenil C₂₋₆)carbonilo, (alquinil C₂₋₆)carbonilo, arilcarbonilo, heteroarilcarbonilo, (alquil C₁₋₆)aminocarbonilo, (alquenil C₂₋₆)aminocarbonilo, (alquinil C₂₋₆)aminocarbonilo, arilaminocarbonilo, heteroarilaminocarbonilo, (alquilsulfonil C₁₋₆)alquilo C₁₋₃, (alquenilsulfonil C₂₋₆)alquilo C₁₋₃, (alquinilsulfonil C₂₋₆)alquilo C₁₋₃, (arilsulfonil)alquilo C₁₋₃, (heteroarilsulfonil)alquilo C₁₋₃, (alquilsulfinil C₁₋₆)alquilo C₁₋₃, (arilsulfinil)alquilo C₁₋₃, (heteroarilsulfinil)alquilo C₁₋₃, (alquil C₁₋₆)aminocarbonilalquilo C₁₋₃, (alquenil C₂₋₆)aminocarbonilalquilo C₁₋₃, (alquinil C₂₋₆)aminocarbonilalquilo C₁₋₃, (arilaminocarbonil)alquilo C₁₋₃ o (heteroarilaminocarbonil)alquilo C₁₋₃; donde las porciones alquilo, alquenilo y alquinilo opcionalmente están parcial o totalmente fluoradas, y cuando Rᵃ es un miembro seleccionado del grupo formado por H y (alquil C₁₋₄)carbonilo, entonces Y no es (alquil C₁₋₆)carbonilo ni arilcarbonilo; Z es un miembro seleccionado del grupo formado por oxígeno; azufre; SO; SO₂; 1,1-ciclopropileno; carbonilo; o metileno opcionalmente sustituido con uno a dos sustituyentes independientemente seleccionados entre halo, hidroxi, alquilo C₁₋₆, alcoxi C₁₋₆, cicloalquilo C₃₋₆ y cicloalquiloxi C₃₋₆; R¹, R² y R³ son cada uno miembros independientemente seleccionados del grupo formado por hidrógeno, halo, hidroxi, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₁₀, cicloalquenilo C₅₋₁₀, alquiloxi C₁₋₆, cicloalquiloxi C₃₋₁₀, ciano y nitro, donde los grupos o porciones alquilo y cicloalquilo están opcionalmente mono- o polisustituidos con flúor, o cuando R¹ y R² están unidos a dos átomos de C adyacentes, R¹ y R² están opcionalmente unidos para formar un puente de alquileno C₃₋₅, alquenileno C₃₋₅ o butadienileno, que opcionalmente está parcial o totalmente fluorado y esta opcionalmente mono- o disustituido con sustituyentes idénticos o diferentes seleccionados entre cloro, hidroxi, alcoxi C₁₋₃ y alquilo C₁₋₃, y en donde uno o dos grupos metileno están opcionalmente reemplazados independientemente entre sí, por O, S, CO, SO, SO₂ o NRᵇ, y en donde uno o dos grupos metino están opcionalmente reemplazados por N; R⁴ y R⁵ son cada uno independientemente miembros seleccionados del grupo formado por hidrógeno, halo, ciano, nitro, hidroxi, alquilo C₁₋₆, cicloalquilo C₃₋₁₀, alquiloxi C₁₋₃ o cicloalquiloxi C₃₋₁₀, donde los grupos o porciones alquilo y cicloalquilo opcionalmente están mono- o polisustituidos con flúor, o cuando R⁴ y R⁵ están unidos a dos átomos de C adyacentes, R⁴ y R⁵ están opcionalmente unidos para formar un puente de alquileno C₃₋₅, alquenileno C₃₋₅ o butadienileno, que opcionalmente está parcial o totalmente fluorado y opcionalmente está mono- o disustituido con sustituyentes idénticos o diferentes seleccionados entre cloro, hidroxi, alcoxi C₁₋₆ y alquilo C₁₋₆, y donde uno o dos grupos metileno están opcionalmente reemplazados independientemente entre sí, por O, S, CO, SO, SO₂ o NRᵇ, y en donde uno o dos grupos metino están opcionalmente reemplazados por N; R⁶, R⁷, R⁸ y R⁹ son cada uno miembros independientemente seleccionados del grupo formado por hidroxi, (alquil C₁₋₁₈)carboniloxi, (alquil C₁₋₁₈)oxicarboniloxi, arilcarboniloxi, aril-(alquil C₁₋₃)carboniloxi, (cicloalquil C₃₋₁₀)carboniloxi, hidrógeno, halo, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquil C₃₋₁₀-alquilo C₁₋₃, cicloalquenil C₅₋₇-alquilo C₁₋₃, arilalquilo C₁₋₃, heteroaril-alquilo C₁₋₃, alquiloxi C₁₋₆, alqueniloxi C₂₋₆, alquiniloxi C₂₋₆, cicloalquiloxi C₃₋₇, cicloalqueniloxi C₅₋₇, ariloxi, heteroariloxi, cicloalquil C₃₋₇-alquiloxi C₁₋₃, cicloalquenil C₅₋₇-alquiloxi C₁₋₃, aril-alquiloxi C₁₋₃, heteroaril-alquiloxi C₁₋₃, aminocarbonilo, hidroxicarbonilo, (alquil C₁₋₄)aminocarbonilo, di-(alquil C₁₋₃)aminocarbonilo, (alquiloxi C₁₋₄)carbonilo, aminocarbonil-alquilo C₁₋₃, (alquil C₁₋₄)aminocarbonil-alquilo C₁₋₃, di-(alquil C₁₋₃)aminocarbonil-alquilo C₁₋₃, hidroxicarbonil-alquilo C₁₋₃, (alquiloxi C₁₋₄)carbonil-alquilo C₁₋₃, cicloalquiloxi C₃₋₇-alquilo C₁₋₃, cicloalqueniloxi C₅₋₇-alquilo C₁₋₃, ariloxi-alquilo C₁₋₃, heteroariloxi-alquilo C₁₋₃, alquilsulfoniloxi C₁₋₄, arilsulfoniloxi, aril-alquil C₁₋₃-sulfoniloxi, trimetilsililoxi, t-butildimetilsililoxi, o ciano; donde los grupos o porciones alquilo, alquenilo, alquinilo, cicloalquilo y cicloalquenilo opcionalmente están parcial o totalmente fluorados y opcionalmente están mono- o disustituidos con sustituyentes independientemente seleccionados entre cloro, hidroxi, alcoxi C₁₋₃ y alquilo C₁₋₃, y en los grupos o porciones cicloalquilo y cicloalquenilo uno o dos grupos metileno están opcionalmente reemplazados independientemente entre sí, por NRᵇ, O, S, CO, SO o SO₂, y cuando Y es hidrógeno o alquilo C₁₋₆, entonces R⁸ y R⁹ son hidroxi; cada Rᵃ es un miembro independientemente seleccionado del grupo formado por H, alquilo C₁₋₆, cicloalquilo C₃₋₆ o (alquil C₁₋₄)carbonilo, donde los grupos o porciones alquilo y cicloalquilo opcionalmente están parcial o totalmente fluorados; cada Rᵇ es un miembro independientemente seleccionado del grupo formado por H, alquilo C₁₋₄ o (alquil C₁₋₄)carbonilo, donde los grupos o porciones alquilo opcionalmente están parcial o totalmente fluorados; cada Rᶜ es un miembro independientemente seleccionado del grupo formado por H, alquilo C₁₋₄, cicloalquilo C₃₋₆, CHRᵈRᵉ, SO₂Rᵈ, C(O)ORᵈ o C(O)NRᵈRᵉ, en donde los grupos alquilo y cicloalquilo opcionalmente están parcial o totalmente fluorados; y Rᵈ y Rᵉ cada uno independientemente representan H o alquilo C₁₋₆, en donde los grupos alquilo opcionalmente están parcial o totalmente fluorados; y sales farmacéuticamente aceptables del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95762507P | 2007-08-23 | 2007-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110796A2 true AR110796A2 (es) | 2019-05-02 |
Family
ID=40378694
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103675A AR068016A1 (es) | 2007-08-23 | 2008-08-22 | Derivados de bencilbenceno, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por sglt |
| ARP180100278A AR110796A2 (es) | 2007-08-23 | 2018-02-06 | Derivados de bencilbenceno |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103675A AR068016A1 (es) | 2007-08-23 | 2008-08-22 | Derivados de bencilbenceno, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por sglt |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US7838499B2 (es) |
| EP (2) | EP3318562A3 (es) |
| JP (1) | JP4809931B2 (es) |
| KR (1) | KR101107425B1 (es) |
| CN (1) | CN101790311B (es) |
| AR (2) | AR068016A1 (es) |
| AU (1) | AU2008288770B2 (es) |
| BR (1) | BRPI0815708B8 (es) |
| CA (1) | CA2697349C (es) |
| CY (1) | CY1119810T1 (es) |
| DK (1) | DK2187742T3 (es) |
| ES (1) | ES2654894T3 (es) |
| HK (1) | HK1254895A1 (es) |
| HR (1) | HRP20180127T1 (es) |
| HU (1) | HUE035947T2 (es) |
| IL (1) | IL203915A (es) |
| LT (1) | LT2187742T (es) |
| MX (1) | MX2010002027A (es) |
| NO (1) | NO2187742T3 (es) |
| NZ (1) | NZ583369A (es) |
| PL (1) | PL2187742T3 (es) |
| PT (1) | PT2187742T (es) |
| RS (1) | RS56822B1 (es) |
| RU (1) | RU2497526C2 (es) |
| SG (1) | SG188800A1 (es) |
| SI (1) | SI2187742T1 (es) |
| TW (1) | TWI434691B (es) |
| UA (1) | UA99924C2 (es) |
| WO (1) | WO2009026537A1 (es) |
| ZA (1) | ZA201001051B (es) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009026537A1 (en) | 2007-08-23 | 2009-02-26 | Theracos, Inc. | Benzylbenzene derivatives and methods of use |
| CN101801371B (zh) | 2007-09-10 | 2012-11-28 | 詹森药业有限公司 | 可用作sglt抑制剂的化合物的制备方法 |
| UA101004C2 (en) | 2007-12-13 | 2013-02-25 | Теракос, Инк. | Derivatives of benzylphenylcyclohexane and use thereof |
| WO2010009243A1 (en) | 2008-07-15 | 2010-01-21 | Theracos, Inc. | Deuterated benzylbenzene derivatives and methods of use |
| AU2014201286B2 (en) * | 2008-08-22 | 2015-07-02 | Theracosbio, Llc | Processes for the preparation of SGLT2 inhibitors |
| PT2324002T (pt) * | 2008-08-22 | 2016-11-09 | Theracos Sub Llc | Processos para a preparação de inibidores de sglt2 |
| MX2011002166A (es) | 2008-08-28 | 2011-04-07 | Pfizer | Derivados de dioxa-biciclo[3.2.1]octano-2,3,1-triol. |
| US9056850B2 (en) | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
| EP2367554A4 (en) * | 2008-11-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | Bile acid reflux inhibitor for the treatment of obesity and diabetes |
| US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
| KR101532412B1 (ko) | 2009-07-10 | 2015-06-29 | 얀센 파마슈티카 엔.브이. | 1-(β-Ｄ-글루코피라노실)-4-메틸-3-(5-(4-플루오로페닐)-2-티에닐메틸) 벤젠의 결정화 방법 |
| US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| NZ599945A (en) | 2009-11-02 | 2014-05-30 | Pfizer | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| WO2011070592A2 (en) | 2009-12-09 | 2011-06-16 | Panacea Biotec Ltd. | Novel sugar derivatives |
| CN102134226B (zh) * | 2010-01-26 | 2013-06-12 | 天津药物研究院 | 一类苯基c-葡萄糖苷衍生物、其制备方法和用途 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| CN102234287B (zh) | 2010-04-26 | 2015-08-05 | 上海阳帆医药科技有限公司 | 硝基咪唑类化合物、其制备方法和用途 |
| EP3593802A3 (en) | 2010-05-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| WO2011153712A1 (en) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| CN102372722A (zh) | 2010-08-10 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用 |
| WO2012025857A1 (en) | 2010-08-23 | 2012-03-01 | Hetero Research Foundation | Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors |
| GB201101959D0 (en) | 2011-02-04 | 2011-03-23 | Univ Nottingham | Novel ether linked compoundsand improved treatments for cardiac and cardiovascular disease |
| WO2012109996A1 (zh) | 2011-02-18 | 2012-08-23 | 上海璎黎科技有限公司 | 一种芳基糖苷类化合物及其制备方法和应用 |
| CN102675378A (zh) * | 2011-03-09 | 2012-09-19 | 天津药物研究院 | 一类含环丙烷结构的c-葡萄糖苷衍生物、其制备方法和用途 |
| AU2012241897C1 (en) | 2011-04-13 | 2017-05-11 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of SGLT2 |
| JP2014512399A (ja) * | 2011-04-25 | 2014-05-22 | ベイジン・プレリュード・ファーム・サイ・アンド・テック・カンパニー・リミテッド | ナトリウム依存性グルコース輸送タンパク質阻害剤並びにその調製方法及び使用 |
| TWI542596B (zh) * | 2011-05-09 | 2016-07-21 | 健生藥品公司 | （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體 |
| WO2013000275A1 (zh) * | 2011-06-25 | 2013-01-03 | 山东轩竹医药科技有限公司 | C-糖苷衍生物 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2755722B1 (en) * | 2011-09-13 | 2017-05-24 | Panacea Biotec Ltd. | Novel sglt inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| KR102051031B1 (ko) | 2011-10-28 | 2019-12-02 | 루메나 파마수티컬즈, 인코포레이티드 | 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제 |
| BR112014010223B8 (pt) | 2011-10-28 | 2021-02-23 | Lumena Pharmaceuticals Llc | uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica |
| US8697658B2 (en) * | 2011-12-15 | 2014-04-15 | National Health Research Institutes | Glycoside compounds |
| WO2013152476A1 (en) * | 2012-04-10 | 2013-10-17 | Theracos, Inc. | Process for the preparation of benzylbenzene sglt2 inhibitors |
| EP2925735B1 (en) | 2012-11-20 | 2019-03-13 | Lexicon Pharmaceuticals, Inc. | Inhibitors of sodium glucose cotransporter 1 |
| CN103910769B (zh) | 2012-12-31 | 2018-10-02 | 上海璎黎药业有限公司 | 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用 |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| US9394329B2 (en) | 2013-09-27 | 2016-07-19 | Sunshine Lake Pharma Co., Ltd. | Glucopyranosyl derivatives and their uses in medicine |
| CN105611920B (zh) | 2013-10-12 | 2021-07-16 | 泰拉科斯萨普有限责任公司 | 羟基-二苯甲烷衍生物的制备 |
| US9315438B2 (en) | 2014-01-03 | 2016-04-19 | Xuanzhu Pharma Co., Ltd | Optically pure benzyl-4-chlorophenyl-C-glucoside derivative |
| CN104031098A (zh) * | 2014-06-21 | 2014-09-10 | 李友香 | 降糖药物 |
| CN104017031A (zh) * | 2014-06-21 | 2014-09-03 | 李友香 | 降血糖药物和组合物 |
| CN104086379B (zh) * | 2014-07-29 | 2015-08-12 | 安徽联创生物医药股份有限公司 | 达格列净中间体的合成方法 |
| JP2016060698A (ja) * | 2014-09-16 | 2016-04-25 | 本田技研工業株式会社 | １，２−ビス（２，２−ジフルオロエトキシ）エタンおよびその製造方法 |
| US9305155B1 (en) * | 2015-02-12 | 2016-04-05 | United Services Automobile Association (Usaa) | Toggling biometric authentication |
| CN105061373B (zh) * | 2015-09-06 | 2017-10-20 | 合肥华方医药科技有限公司 | 一种达格列净异构体杂质的合成方法 |
| US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
| UA122083C2 (uk) * | 2016-01-04 | 2020-09-10 | Че Іль Фармасьютікал Ко., Лтд. | C-глікозидні похідні, які містять конденсоване фенільне кільце, або їхні фармацевтично прийнятні солі, спосіб одержання таких і фармацевтична композиція, що містить такі |
| CN105770861B (zh) * | 2016-04-08 | 2020-02-28 | 吴一行 | 一种用于治疗男性糖尿病患者勃起功能障碍的药物 |
| WO2018207111A1 (en) | 2017-05-09 | 2018-11-15 | Piramal Enterprises Limited | A process for the preparation of sglt2 inhibitors and intermediates thereof |
| WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
| WO2020084559A1 (en) | 2018-10-26 | 2020-04-30 | Janssen Pharmaceutica Nv | Glucopyranose derivatives useful as sglt2 inhibitors |
| US20210388016A1 (en) | 2018-10-26 | 2021-12-16 | Janssen Pharmaceutica Nv | Glucopyranose derivatives useful as sglt2 inhibitors |
| CA3132990A1 (en) * | 2019-03-14 | 2020-09-17 | Increvet, Inc. | A compound for the management of feline diabetes |
| US20230000816A1 (en) * | 2019-11-07 | 2023-01-05 | Increvet, Inc. | Sodium-glucose linked transporter inhibitors for the management of chronic kidney disease, hypertension, and heart failure in companion animals |
| CN114599643B (zh) * | 2020-05-15 | 2023-04-14 | 上海喆邺生物科技有限公司 | 一种芳基葡糖苷衍生物 |
| CN111662166A (zh) * | 2020-05-28 | 2020-09-15 | 吴赣药业（苏州）有限公司 | 一种5-溴-2-氯-4′-乙氧基二苯甲烷的制备方法 |
| WO2022073151A1 (en) | 2020-10-05 | 2022-04-14 | Theracos Sub, Llc | Pharmaceutical formulations |
| EP4531810A1 (en) | 2022-05-25 | 2025-04-09 | Boehringer Ingelheim Vetmedica GmbH | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
| US20240307628A1 (en) | 2023-03-06 | 2024-09-19 | Boehringer Ingelheim Vetmedica Gmbh | Systems and methods for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s) |
| WO2024240632A1 (en) | 2023-05-24 | 2024-11-28 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan |
| KR20260019532A (ko) | 2023-05-24 | 2026-02-10 | 베링거잉겔하임베트메디카게엠베하 | 하나 이상의 sglt-2 억제제와 텔미사르탄을 포함하는 비인간 포유류의 신장 질환 및/또는 고혈압의 병용 치료 및/또는 예방 |
| WO2025056984A1 (en) * | 2023-09-12 | 2025-03-20 | Vijayasri Organics Private Limited | A novel process for the preparation of bexagliflozin a sglt2 inhibitor and its intermediates thereof |
| CN117343115A (zh) * | 2023-10-18 | 2024-01-05 | 宁波工程学院 | 基于扭转结构特征的酰胺为原料合成糖缀合物的方法 |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4499289A (en) | 1982-12-03 | 1985-02-12 | G. D. Searle & Co. | Octahydronapthalenes |
| US4933438A (en) | 1984-02-29 | 1990-06-12 | University Of Florida | Brain-specific analogues of centrally acting amines |
| US4613610A (en) | 1984-06-22 | 1986-09-23 | Sandoz Pharmaceuticals Corp. | Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives |
| US4686237A (en) | 1984-07-24 | 1987-08-11 | Sandoz Pharmaceuticals Corp. | Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof |
| US4647576A (en) | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
| US6150354A (en) | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
| US4871721A (en) | 1988-01-11 | 1989-10-03 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors |
| US4924024A (en) | 1988-01-11 | 1990-05-08 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors, new intermediates and method |
| US5506219A (en) | 1988-08-29 | 1996-04-09 | E. R. Squibb & Sons, Inc. | Pyridine anchors for HMG-CoA reductase inhibitors |
| US5753675A (en) | 1989-03-03 | 1998-05-19 | Novartis Pharmaceuticals Corporation | Quinoline analogs of mevalonolactone and derivatives thereof |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| EP0584185B1 (en) | 1991-05-14 | 1999-08-11 | Ernir Snorrason | Treatment of fatigue syndrome with cholinesterase inhibitors |
| IT1250421B (it) | 1991-05-30 | 1995-04-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive. |
| US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
| US5712396A (en) | 1992-10-28 | 1998-01-27 | Magnin; David R. | α-phosphonosulfonate squalene synthetase inhibitors |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| FR2710265B1 (fr) | 1993-09-22 | 1995-10-20 | Adir | Composition pharmaceutique bioadhésive pour la libération contrôlée de principes actifs. |
| US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
| US6548084B2 (en) | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
| US6245347B1 (en) | 1995-07-28 | 2001-06-12 | Zars, Inc. | Methods and apparatus for improved administration of pharmaceutically active compounds |
| WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| DE19541260A1 (de) | 1995-11-06 | 1997-05-07 | Lohmann Therapie Syst Lts | Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut |
| US5962440A (en) | 1996-05-09 | 1999-10-05 | Bristol-Myers Squibb Company | Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method |
| US5885983A (en) | 1996-05-10 | 1999-03-23 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US6512010B1 (en) | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
| US6011155A (en) | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
| EA002806B1 (ru) | 1997-09-11 | 2002-10-31 | Нюкомед Данмарк А/С | Многоединичные композиции с модифицированным высвобождением нестероидных противовоспалительных лекарственных веществ (nsaid) |
| US6624200B2 (en) | 1998-08-25 | 2003-09-23 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| US6607751B1 (en) | 1997-10-10 | 2003-08-19 | Intellipharamaceutics Corp. | Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum |
| US6403597B1 (en) | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| US6248864B1 (en) | 1997-12-31 | 2001-06-19 | Adherex Technologies, Inc. | Compounds and methods and modulating tissue permeability |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6312717B1 (en) | 1998-07-07 | 2001-11-06 | Bristol-Myers Squibb Company | Method for treatment of anxiety and depression |
| US6197798B1 (en) | 1998-07-21 | 2001-03-06 | Novartis Ag | Amino-benzocycloalkane derivatives |
| US20020009478A1 (en) | 1998-08-24 | 2002-01-24 | Douglas Joseph Dobrozsi | Oral liquid mucoadhesive compositions |
| SE9802864D0 (sv) | 1998-08-27 | 1998-08-27 | Pharmacia & Upjohn Ab | Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder |
| CN1406126A (zh) | 1998-10-01 | 2003-03-26 | 诺瓦提斯公司 | 新型缓释口服制剂 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
| FR2792527B1 (fr) | 1999-04-22 | 2004-08-13 | Ethypharm Lab Prod Ethiques | Microgranules de ketoprofene, procede de preparation et compositions pharmaceutiques |
| US6172081B1 (en) | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
| US6541020B1 (en) | 1999-07-09 | 2003-04-01 | Trimeris, Inc. | Methods and compositions for administration of therapeutic reagents |
| DE19933926A1 (de) | 1999-07-20 | 2001-01-25 | Boehringer Ingelheim Pharma | Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
| US6562375B1 (en) | 1999-08-04 | 2003-05-13 | Yamanouchi Pharmaceuticals, Co., Ltd. | Stable pharmaceutical composition for oral use |
| DE60036874T2 (de) | 1999-09-02 | 2008-06-26 | Nostrum Pharmaceuticals Inc. | Pellet formulierung mit gesteuerter freisetzung |
| US6544548B1 (en) | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| PH12000002657B1 (en) * | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| CN1896088A (zh) * | 1999-10-12 | 2007-01-17 | 布里斯托尔-迈尔斯斯奎布公司 | C－芳基葡糖苷sglt2抑制剂 |
| US6080736A (en) | 1999-10-27 | 2000-06-27 | Janus Pharmaceuticals, Inc. | Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| DE19963234A1 (de) | 1999-12-27 | 2002-01-24 | Boehringer Ingelheim Pharma | Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
| US6482439B2 (en) | 1999-12-29 | 2002-11-19 | Nanodelivery, Inc. | Drug delivery system exhibiting permeability control |
| US6878707B2 (en) | 2000-01-18 | 2005-04-12 | Novartis Ag | Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion |
| EP1253925A1 (en) | 2000-01-28 | 2002-11-06 | Bristol-Myers Squibb Company | Tetrahydropyrimidone inhibitors of fatty acid binding protein and method |
| US6555519B2 (en) | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
| US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
| US6589549B2 (en) | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
| US6524621B2 (en) | 2000-05-01 | 2003-02-25 | Aeropharm Technology Inc. | Core formulation |
| US6432969B1 (en) | 2000-06-13 | 2002-08-13 | Novartis Ag | N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US6482440B2 (en) | 2000-09-21 | 2002-11-19 | Phase 2 Discovery, Inc. | Long acting antidepressant microparticles |
| HUP0500543A2 (hu) | 2000-11-20 | 2005-09-28 | Bristol-Myers Squibb Company | Piridonszármazékok mint aP2 inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények |
| US6524615B2 (en) | 2001-02-21 | 2003-02-25 | Kos Pharmaceuticals, Incorporated | Controlled release pharmaceutical composition |
| KR100388682B1 (ko) * | 2001-03-03 | 2003-06-25 | 삼성전자주식회사 | 반도체 메모리 장치의 스토리지 전극층 및 그 형성방법 |
| US6936590B2 (en) * | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| ES2258141T3 (es) | 2001-04-11 | 2006-08-16 | Bristol-Myers Squibb Company | Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento. |
| US6869947B2 (en) | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| US6919323B2 (en) | 2001-07-13 | 2005-07-19 | Bristol-Myers Squibb Company | Pyridazinone inhibitors of fatty acid binding protein and method |
| US20030087843A1 (en) | 2001-09-05 | 2003-05-08 | Washburn William N. | O-pyrazole glucoside SGLT2 inhibitors and method of use |
| WO2003043624A1 (en) | 2001-11-16 | 2003-05-30 | Bristol-Myers Squibb Company | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein |
| US6727261B2 (en) | 2001-12-27 | 2004-04-27 | Hoffman-La Roche Inc. | Pyrido[2,1-A]Isoquinoline derivatives |
| US6710040B1 (en) | 2002-06-04 | 2004-03-23 | Pfizer Inc. | Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors |
| US7375087B2 (en) | 2002-08-08 | 2008-05-20 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| AU2003254903B9 (en) | 2002-08-09 | 2008-08-21 | Taisho Pharmaceutical Co., Ltd. | Method for selective preparation of aryl 5-thio-beta-D-aldohexopyranosides |
| AU2003299966A1 (en) | 2003-01-03 | 2004-08-10 | Bristol-Myers Squibb Company | Methods of producing c-aryl glucoside sglt2 inhibitors |
| CN1802366B (zh) | 2003-03-14 | 2010-12-22 | 安斯泰来制药有限公司 | C-糖苷衍生物及其盐 |
| JP2004300102A (ja) | 2003-03-31 | 2004-10-28 | Kissei Pharmaceut Co Ltd | 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途 |
| WO2005005237A1 (en) | 2003-07-02 | 2005-01-20 | Keith Gilstrap | Handlebar/stem mounted bicycle wheel holding device |
| AU2004261660A1 (en) | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica N.V. | Substituted fused heterocyclic C-glycosides |
| MXPA06001274A (es) | 2003-08-01 | 2006-04-11 | Tanabe Seiyaku Co | Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio. |
| TW200524951A (en) | 2003-08-01 | 2005-08-01 | Janssen Pharmaceutica Nv | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides |
| WO2005021566A2 (de) | 2003-08-26 | 2005-03-10 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| US7375090B2 (en) | 2003-08-26 | 2008-05-20 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof |
| US20070054887A1 (en) * | 2003-09-24 | 2007-03-08 | Bioxell S.P.A | Methods for treating bladder dysfunction |
| US7371732B2 (en) | 2003-12-22 | 2008-05-13 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture |
| DE10361133A1 (de) | 2003-12-22 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Glucopyranosyloxy-substituierte Aromaten, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| WO2005085237A1 (ja) | 2004-03-04 | 2005-09-15 | Kissei Pharmaceutical Co., Ltd. | 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途 |
| EP2360165A3 (de) | 2004-03-16 | 2012-01-04 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituierte Benzol-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE102004012676A1 (de) * | 2004-03-16 | 2005-10-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE102004061145A1 (de) * | 2004-12-16 | 2006-06-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Glucopyranosyl-substituierte Benzol-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE102004040168A1 (de) * | 2004-08-18 | 2006-03-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| CA2560005A1 (en) | 2004-03-31 | 2005-10-13 | Kissei Pharmaceutical Co., Ltd. | Phenol derivative, medicinal composition containing the same, and medicinal use thereof |
| US7393836B2 (en) | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
| DE102004034690A1 (de) | 2004-07-17 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| TW200606129A (en) | 2004-07-26 | 2006-02-16 | Chugai Pharmaceutical Co Ltd | Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same |
| EP1773800A1 (de) | 2004-07-27 | 2007-04-18 | Boehringer Ingelheim International GmbH | D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| WO2006018150A1 (de) | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| AR051446A1 (es) * | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
| DE102004048388A1 (de) | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| WO2006064033A2 (en) * | 2004-12-16 | 2006-06-22 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| TW200637839A (en) | 2005-01-07 | 2006-11-01 | Taisho Pharmaceutical Co Ltd | 1-thio-d-glucitol derivatives |
| TW200637869A (en) | 2005-01-28 | 2006-11-01 | Chugai Pharmaceutical Co Ltd | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same |
| WO2006089872A1 (en) * | 2005-02-23 | 2006-08-31 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ( (hetero)arylethynyl-benzyd-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors |
| US7975805B2 (en) | 2005-04-01 | 2011-07-12 | Oil-Rite Corporation | Lubrication system |
| ATE453656T1 (de) | 2005-04-15 | 2010-01-15 | Boehringer Ingelheim Int | Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren |
| UA91546C2 (uk) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| WO2007000445A1 (en) | 2005-06-29 | 2007-01-04 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| ES2346347T3 (es) | 2005-07-27 | 2010-10-14 | Boehringer Ingelheim International Gmbh | Derivados de ((hetero)cicloalquiletinil-bencil)-benceno y su uso como inhibidores del cotransportador de glucosa dependiente de sodio (sglt). |
| ATE484499T1 (de) | 2005-08-30 | 2010-10-15 | Boehringer Ingelheim Int | Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür |
| CN101238112A (zh) | 2005-09-08 | 2008-08-06 | 贝林格尔·英格海姆国际有限公司 | 1-氯-4-(β-D-吡喃葡萄糖-1-基)-2-(4-乙炔基-苄基)-苯的晶形、其制备方法及其用于制备药物中的用途 |
| TW200812995A (en) | 2006-05-19 | 2008-03-16 | Taisho Pharmaceutical Co Ltd | C-phenyl glycitol compound |
| WO2009026537A1 (en) * | 2007-08-23 | 2009-02-26 | Theracos, Inc. | Benzylbenzene derivatives and methods of use |
| PT2324002T (pt) * | 2008-08-22 | 2016-11-09 | Theracos Sub Llc | Processos para a preparação de inibidores de sglt2 |
-
2008
- 2008-08-22 WO PCT/US2008/074058 patent/WO2009026537A1/en not_active Ceased
- 2008-08-22 RS RS20180074A patent/RS56822B1/sr unknown
- 2008-08-22 US US12/197,095 patent/US7838499B2/en active Active
- 2008-08-22 NO NO08798514A patent/NO2187742T3/no unknown
- 2008-08-22 HU HUE08798514A patent/HUE035947T2/hu unknown
- 2008-08-22 AU AU2008288770A patent/AU2008288770B2/en not_active Ceased
- 2008-08-22 UA UAA201003326A patent/UA99924C2/ru unknown
- 2008-08-22 BR BRPI0815708A patent/BRPI0815708B8/pt active IP Right Grant
- 2008-08-22 MX MX2010002027A patent/MX2010002027A/es active IP Right Grant
- 2008-08-22 SI SI200831898T patent/SI2187742T1/en unknown
- 2008-08-22 EP EP17190414.7A patent/EP3318562A3/en not_active Withdrawn
- 2008-08-22 KR KR1020107006207A patent/KR101107425B1/ko active Active
- 2008-08-22 EP EP08798514.9A patent/EP2187742B1/en active Active
- 2008-08-22 CN CN200880104132.1A patent/CN101790311B/zh active Active
- 2008-08-22 ES ES08798514.9T patent/ES2654894T3/es active Active
- 2008-08-22 RU RU2010110829/15A patent/RU2497526C2/ru active
- 2008-08-22 HR HRP20180127TT patent/HRP20180127T1/hr unknown
- 2008-08-22 NZ NZ583369A patent/NZ583369A/en not_active IP Right Cessation
- 2008-08-22 PT PT87985149T patent/PT2187742T/pt unknown
- 2008-08-22 TW TW097132255A patent/TWI434691B/zh active
- 2008-08-22 AR ARP080103675A patent/AR068016A1/es active IP Right Grant
- 2008-08-22 DK DK08798514.9T patent/DK2187742T3/en active
- 2008-08-22 CA CA2697349A patent/CA2697349C/en active Active
- 2008-08-22 LT LTEP08798514.9T patent/LT2187742T/lt unknown
- 2008-08-22 PL PL08798514T patent/PL2187742T3/pl unknown
- 2008-08-22 JP JP2010522073A patent/JP4809931B2/ja active Active
- 2008-08-22 SG SG2013012877A patent/SG188800A1/en unknown
-
2010
- 2010-02-11 IL IL203915A patent/IL203915A/en active IP Right Grant
- 2010-02-12 ZA ZA2010/01051A patent/ZA201001051B/en unknown
- 2010-11-01 US US12/917,367 patent/US8106021B2/en active Active
-
2011
- 2011-12-21 US US13/333,295 patent/US8575321B2/en active Active
-
2013
- 2013-09-30 US US14/042,408 patent/US8802637B2/en active Active
-
2018
- 2018-01-22 CY CY20181100079T patent/CY1119810T1/el unknown
- 2018-02-06 AR ARP180100278A patent/AR110796A2/es unknown
- 2018-11-01 HK HK18113993.0A patent/HK1254895A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110968A2 (es) | Derivados de glicósido bencílico y composición farmacéutica | |
| AR068016A1 (es) | Derivados de bencilbenceno, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por sglt | |
| AR057104A1 (es) | Diaminopirimidinas como moduladores de p2 x3 y p2x2 /3 y composicion farmaceutica | |
| AR060651A1 (es) | Derivados de 1,2,4-triazol como moduladores de mglur5 i, intermediarios para su sintesis, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del dolor y de trastornos gastrointestinales | |
| AR092490A2 (es) | Indolil alquil amino derivados sustituidos como inhibidores de la histona desacetilasa | |
| AR054320A1 (es) | Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos. composiciones farmaceuticas | |
| PE20130774A1 (es) | Compuestos heterociclicos activadores de ampk y metodos para emplearlos | |
| CR10922A (es) | Derivados de indol como antagonistas receptores de s1p1 | |
| PE20091429A1 (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas como inhibidores de la elastasa neutrofila humana (hne) | |
| AR059778A1 (es) | Compuestos de pirrolotriazina inhibidores de quinasas p38,composiciones farmaceuticas que los contienen y usos en gran variedad de procesos inflamatorios. | |
| AR067673A1 (es) | Derivados de 1,3 oxazinan - 2 - ona como inhibidores ciclicos de la 11 beta -hidroxiesteroide deshidrogenasa 1. composiciones farmaceuticas. | |
| PE20081362A1 (es) | DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K | |
| PE20120008A1 (es) | Derivados de fenoxi bencenosulfonamida | |
| AR077440A1 (es) | Bencenosulfonamidas como bloqueadores de canales de calcio y composiciones farmaceuticas | |
| DE602007009420D1 (de) | Oxadiazolderivate als s1p1-rezeptor-agonisten | |
| ATE496620T1 (de) | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren | |
| PE20081851A1 (es) | Derivados de espiropiperidina-glicinamida | |
| PE20091090A1 (es) | Derivados de piperidina como agonistas de receptores muscarinicos | |
| AR111756A1 (es) | 4-difluorometilbenzoilamidas de acción herbicida | |
| AR069814A1 (es) | Derivados de 4 amino-pirimidina, proceso de preparacion y composiciones farmaceuticas que los contienen | |
| PE20081227A1 (es) | Derivados indazolil sulfonamidas como moduladores de glucocorticoides | |
| AR079550A1 (es) | Derivados de pirazol | |
| AR058010A1 (es) | Derivados biciclicos como inhibidores de p38 y composicion farmaceutica en base al compuesto | |
| PE20091433A1 (es) | Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procedimientos para su preparacion 177 | |
| AR107965A2 (es) | Derivados de pirimidina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |